SCHEMBL18919971

SCHEMBL18919971

COc1c(F)cccc1S(=O)(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
KRAS P01116 2/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 2/20 0.38
MAPK1 P28482 1/20 0.38
CCR4 P51679 2/20 0.37
KAT6A Q92794 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
NFE2L2 Q16236 1/20 0.35
PTGES2 Q9H7Z7 2/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
BCHE P06276 1/20 0.34
HTR6 P50406 1/20 0.33
POLB P06746 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11138757 0.86 TRPV4 (0.46) TRPV4SMN1; SMN2KMT2AMAPK1CCR4
SCHEMBL18700967 0.81 KRAS (0.41) SMN1; SMN2KRASKMT2AGAAMAPK1
SCHEMBL24314190 0.81 TRPV4 (0.40) TRPV4MAPK1KAT6AALDH1A1
Hydrochloric Acid SCHEMBL28247004 0.80 KRAS (0.40) SMN1; SMN2KRASKMT2AGAAMAPK1
SCHEMBL4609432 0.79 TRPV4 (0.41) TRPV4SMN1; SMN2KMT2AGAAMAPK1
SCHEMBL1713241 0.79 TRPV4 (0.49) TRPV4SMN1; SMN2NFE2L2HTR6
SCHEMBL4306061 0.79 TRPV4 (0.44) TRPV4CCR4ALDH1A1NFE2L2
SCHEMBL29969255 0.79 TRPV4 (0.49) TRPV4SMN1; SMN2NFE2L2HTR6
SCHEMBL15189949 0.78 TRPV4 (0.47) TRPV4SMN1; SMN2KMT2AALDH1A1PKM
SCHEMBL31579436 0.78 TRPV4 (0.40) TRPV4KMT2ACCR4HTR6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 WO disclosed
US-12065399-B2 Arylsulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2024-08-20 US disclosed
EP-4013495-B1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS HOFFMANN LA ROCHE (CH) 2023-09-27 EP disclosed
EP-4013495-B1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS HOFFMANN LA ROCHE (CH) 2023-09-27 EP disclosed
EP-4013495-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. Hoffmann-La Roche AG (CH) 2022-06-22 EP disclosed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US disclosed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US disclosed
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN disclosed
WO-2021028512-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2021-02-18 WO disclosed
WO-2021028512-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2021-02-18 WO disclosed
US-20180334436-A1 TETRAHYDROISOQUINOLINE DERIVATIVES VIIV HEALTHCARE UK LIMITED (GB) 2018-11-22 US disclosed
EP-3383866-A1 TETRAHYDROISOQUINOLINE DERIVATIVES ViiV Healthcare UK Limited (GB) 2018-10-10 EP disclosed
CN-107207527-A Pyridooxazinone compounds as TNAP inhibitors 第三共株式会社 2017-09-26 CN disclosed
WO-2017093938-A1 TETRAHYDROISOQUINOLINE DERIVATIVES VIIV HEALTHCARE UK LIMITED (GB) 2017-06-08 WO disclosed
CN-106699692-A Piperazinyl urea derivative as well as preparation method and application thereof 上海医药工业研究院 2017-05-24 CN disclosed
CN-104334527-B Sulfonamide compounds and uses as tnap inhibitors 桑福德-伯纳姆医学研究院 2017-05-24 CN disclosed
CN-104334527-A Sulfonamide compounds and uses as tnap inhibitors SANFORD BURNHAM MED RES INST 2015-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES ARSA, SULT1E1, STS TRPV4 3494/4885SMN1; SMN2 1681/4885KRAS 316/4885
US-12065399-B2 Arylsulfonamide derivatives ARSA, SULT1E1, STS TRPV4 3494/4885SMN1; SMN2 1681/4885KRAS 316/4885
US-20180334436-A1 TETRAHYDROISOQUINOLINE DERIVATIVES MAVS, EIF2AK2, SARS1 TRPV4 3936/4885SMN1; SMN2 1550/4885KRAS 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.